



KABRA DRUGS LIMITED					
CIN:- L02423MP1989PLC005438					
Regd Offc: 208 Swadesh Bhavan, 2 Press Complex, AB Road, Indore R.S.S.Nagar, Indore, Madhya Pradesh, India, 452011					
(Rs. In Lakhs)					
Statement of Standalone Audited Financial Results for the Quarter and Financial Year Ended 31st March, 2025					
Sr. No	Particulars	For the Quarter Ended		For the Financial Year Ended	
		March 31, 2025	December 31, 2024	March 31, 2024	March 31, 2024
		Audited	Unaudited	Audited	Audited
1	Income				
	Revenue from Operations	-	-	-	-
	Other Income	64.02	-	-	-
	Total Income	64.02	-	-	-
2	Expenses				
	Cost of Material Consumed	-	-	-	-
	Purchase of Stock-in-Trade	-	-	-	-
	Change in inventories of finished goods & work in progress	-	-	-	-
	Employee Benefit Expense	25.13	19.21	12.49	40.04
	Financial costs	-	-	-	-
	Depreciation & Amortisation Expense	0.55	0.13	-	-
	Other Expenses	(0.93)	34.27	24.58	33.57
	Total Expenses	24.75	53.61	37.07	73.61
3	Profit/(loss) before exceptional items and tax (1-2)	39.26	(53.61)	(37.07)	(73.61)
4	Exceptional Items	-	-	-	-
5	Profit/(loss) before tax (3+4)	39.26	(53.61)	(37.07)	(73.61)
6	Tax Expense:				
	(1) Current Tax				
	- Income Tax	-	-	-	-
	(2) Earlier Year Tax				
	- Short/(Excess) Provision of Tax	-	-	-	-
	(3) Deferred Tax	(0.10)	0.07	-	-
	(4) MAT Credit entitlement		-	-	-
	Total Tax Expenses	(0.10)	0.07	-	-
7	Net Profit/(Loss) after Tax (5-6)	39.36	(53.69)	(37.07)	(73.61)
8	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total Comprehensive Income for the period (7±8)	39.36	(53.69)	(37.07)	(73.61)
10	Paid-up equity share capital (Face Value of Rs.10/- each)	2,370.79	1,007.91	438.86	438.86
11	Reserves excluding Revaluation Reserve as per Balance Sheet	-	-	-	(585.57)
12	Earning per equity share (of Rs. 10/- each) (not annualised):				
	(a) Basic (Rs.)	0.21	(0.53)	(0.84)	(1.68)
	(b) Diluted (Rs.)	0.21	(0.53)	(0.84)	(1.68)
Notes:					
1 The above Audited Standalone Financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 30th May, 2025.					
2 The Financial Results have been audited by the Statutory Auditors as required under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.					
3 Company has only one segment and hence no separate segment result has been given.					
4 The Other expenses for the current quarter is reported as negative due to reclassification of expenses reported in previous quarters.					
5 The figures of the previous year/periods have been regrouped/recast to render them comparable with the figures of the current period.					
6 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.					
<div>For and on Behalf of the Board of directors of Kabra Drugs Limited</div> <div></div> <div>Place: Indore Date: 30-05-2025</div> <div>Nanjappan Aravind Managing Director DIN: 01895602</div>					

KABRA DRUGS LIMITED CIN:- L02423MP1989PLC005438 Regd Offc: 208 Swadesh Bhavan, 2 Press Complex, AB Road, Indore R.S.S.Nagar, Indore, Madhya Pradesh, India, 452011		
(Rs. In Lakhs)		
Standalone Statement Of Assets And Liabilities As At 31st March, 2025		
Particulars	As at March 31, 2025	As at March 31, 2024
ASSETS	Audited	Audited
(1) Non-Current Assets		
(a) Property, plant and equipment	4.39	-
(b) Other Intangible Assets	-	-
(c) Financial Assets		
(i) Other Financial Assets	-	-
(d) Deferred Tax Assets (Net)	-	-
(e) Other non-current assets	2.32	2.32
TOTAL NON-CURRENT ASSETS	6.71	2.32
(2) Current Assets		
(a) Inventories	-	-
(b) Financial Assets		
(i) Trade Receivables	60.05	60.05
(ii) Cash & Cash Equivalents	2,129.93	267.10
(iii) Bank Balance other than (ii) above	-	-
(iv) Loans	-	-
(v) Others	4.36	4.36
(c) Other Current Assets	321.86	123.34
TOTAL CURRENT ASSETS	2,516.19	454.84
TOTAL ASSETS	2,522.90	457.15
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	2,370.79	438.86
(b) Other Equity	94.68	(585.57)
(c) Share Application Money	-	255.00
TOTAL EQUITY	2,465.46	108.29
LIABILITIES		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(b) Deferred Tax Liabilities (Net)	0.05	-
TOTAL NON-CURRENT LIABILITIES	0.05	-
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	43.74	170.85
(ii) Trade Payables	-	-
(iii) Other financial liability	-	-
(b) Other Current Liabilities	13.65	178.02
TOTAL CURRENT LIABILITIES	57.39	348.87
TOTAL EQUITY AND LIABILITIES	2,522.90	457.15
Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.		
<div> <div>  </div> <div> For and on Behalf of the Board of directors of Kabra Drugs Limited Nanjappan Aravind Managing Director DIN: 01895602 </div> </div>		
Place: Indore		
Date: 30-05-2025		

KABRA DRUGS LTD. CIN:- L02423MP1989PLC005438 Regd Offc: 208 Swadesh Bhavan, 2 Press Complex, AB Road, Indore R.S.S.Nagar, Indore, Madhya Pradesh, India, 452011		
(Rs. In Lakhs)		
Standalone Statement of Cash Flows For the Financial Year Ended 31st March, 2025		
Particulars	Financial Year Ended	Financial Year Ended
	March 31, 2025	March 31, 2024
	Audited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax and extra ordinary items	(108.51)	(73.61)
Adjustment For :		
Depreciation/amortization on continuing operation	0.73	-
Interest expenses	-	-
Interest Income	-	-
Excess allowance for doubtful debts reversed	-	-
Loss on sale of Fixed assets	-	-
Operating profit before working capital changes	(107.78)	(73.61)
Changes in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	0.00	-
Increase/(decrease) in Short Term Loan & Advances	-	-
Increase/(decrease) in Current Liabilities	(164.37)	172.75
Increase/(decrease) in Trade Payable	-	0.00
Increase/(decrease) in Other Current Assets	(198.53)	(119.99)
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities (A)	(470.68)	(20.85)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments /withdrawl in Partnership Firm	-	-
Purchase / Sale of Fixed Assets	(5.13)	-
Interest Received	-	-
Change in Bank balances not considered as cash	-	-
Increase/(decrease) in Long Term Loan & Advances	-	-
Increase/(decrease) in other non-current Asset	-	-
Net Cash Flow from Investing Activities (B)	(5.13)	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	(127.11)	32.66
Proceeds from issue of equity shares less issue costs	2,465.74	255.00
Net Cash Flow from Financing Activities (C)	2,338.63	287.66
Net increase/(decrease) in cash & cash equivalents(A+B+C)	1,862.83	266.80
Cash and Cash equivalents (Opening Balance)	267.10	0.29
Cash and Cash equivalents (Closing Balance)	2,129.93	267.10
Notes: 1. Statement of Cash Flows has been prepared using Indirect Method as per Ind AS 7 Statement of Cash Flows 2. Previous Year figures have been regrouped/rclassified, wherever necessary to correspond with the current year's presentation/ disclosure		
<div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div style="text-align: center;">  </div> <div style="text-align: right;"> For and on Behalf of the Board of directors of Kabra Drugs Limited Nanjappan Aravind Managing Director DIN: 01895602 </div> </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div> Place: Indore Date: 30-05-2025 </div> </div>		